Comparison of P450 enzymes between cynomolgus monkeys and humans: P450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles

Current Drug Metabolism

Volumn 14, Issue 2, 2013, Pages 239-252

  Emoto, Chie ^a   Yoda, Noriaki ^a   Uno, Yasuhiro ^b   Iwasaki, Kazuhide ^b   Umehara, Ken ^a   Kashiyama, Eiji ^a   Yamazaki, Hiroshi ^c  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cynomolgus monkey; Human; Intestine; Liver; Metabolism; P450

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2A; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A; SULFAPHENAZOLE;

ARTICLE; ENZYME ACTIVITY; HUMAN; HYDROXYLATION; KINETICS; LIVER MICROSOME; NONHUMAN; OXIDATION; PROTEIN CONTENT; PROTEIN EXPRESSION; REVIEW;

EID: 84877950996     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211314020012     Document Type: Article

References (103)

1. Albert, P.L. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today, 2001, 6(7), 357-366.
2. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3(8), 711-716.
3. Emoto, C.; Murayama, N.; Rostami-Hodjegan, A.; Yamazaki, H. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr. Drug Metab., 2010, 11(8), 678-685.
4. Deguchi, T.; Watanabe, N.; Kurihara, A.; Igeta, K.; Ikenaga, H.; Fusegawa, K.; Suzuki, N.; Murata, S.; Hirouchi, M.; Furuta, Y.; Iwasaki, M.; Okazaki, O.; Izumi, T. Human pharmacokinetic prediction of UDP- glucuronosyltransferase substrates with an animal scale-up approach. Drug Metab. Dispos., 2011, 39(5), 820-829.
5. Wienkers, L.C.; Heath, T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov., 2005, 4(10), 825-833. (Pubitemid 41553963)
6. Williams, J.A.; Hyland, R.; Jones, B.C.; Smith, D.A.; Hurst, S.; Goosen, T.C.; Peterkin, V.; Koup, J.R.; Ball, S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 2004, 32(11), 1201-1208. (Pubitemid 39410902)
7. Guengerich, F.P. Reactions and significance of cytochrome P-450 enzymes. J. Biol. Chem., 1991, 266(16), 10019-10022.
8. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 1994, 270(1), 414-423. (Pubitemid 24229655)
9. Krishna, D.R.; Klotz, U. Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet., 1994, 26(2), 144-160. (Pubitemid 24064238)
10. Paine, M.F.; Khalighi, M.; Fisher, J.M.; Shen, D.D.; Kunze, K.L.; Marsh, C.L.; Perkins, J.D.; Thummel, K.E. Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. J. Pharmacol. Exp. Ther., 1997, 283(3), 1552-1562. (Pubitemid 28016533)
11. Spatzenegger, M.; Jaeger, W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab. Rev., 1995, 27(3), 397-417.
12. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev., 2002, 34(1-2), 83-448. (Pubitemid 34311090)
13. Kato, M.; Chiba, K.; Hisaka, A.; Ishigami, M.; Kayama, M.; Mizuno, N.; Nagata, Y.; Takakuwa, S.; Tsukamoto, Y.; Ueda, K.; Kusuhara, H.; Ito, K.; Sugiyama, Y. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab. Pharmacokinet., 2003, 18(6), 365-372.
14. Obach, R.S.; Baxter, J.G.; Liston, T.E.; Silber, B.M.; Jones, B.C.; MacIntyre, F.; Rance, D.J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther., 1997, 283(1), 46-58. (Pubitemid 27438945)
15. Obach, R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 1999, 27(11), 1350-1359.
16. Emoto, C.; Murayama, N.; Rostami-Hodjegan, A.; Yamazaki, H. Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drugdiscovery stage: Impact of plasma and microsomal binding. Xenobiotica, 2009, 39(3), 227-235.
17. Shibata, Y.; Takahashi, H.; Ishii, Y. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab. Dispos., 2000, 28(12), 1518-1523.
18. Yang, J.; Jamei, M.; Yeo, K.R.; Tucker, G.T.; Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab., 2007, 8(7), 676-684. (Pubitemid 47578116)
19. Kupferschmidt, H.H.; Ha, H.R.; Ziegler, W.H.; Meier, P.J.; Krahenbuhl, S. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther., 1995, 58(1), 20-28.
20. Iwasaki, K.; Uno, Y. Cynomolgus monkey CYPs: a comparison with human CYPs. Xenobiotica, 2009, 39(8), 578-581.
21. Ward, K.W.; Smith, B.R. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab. Dispos., 2004, 32(6), 603-611. (Pubitemid 38668152)
22. Nishimuta, H.; Sato, K.; Mizuki, Y.; Yabuki, M.; Komuro, S. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Drug Metab. Pharmacokinet., 2011, 26(3), 300-306.
23. Komori, M.; Kikuchi, O.; Kitada, M.; Kamataki, T. Molecular cloning of monkey P450 1A1 cDNA and expression in yeast. Biochim. Biophys. Acta., 1992, 1131(1), 23-29.
24. Uno, Y.; Iwasaki, K.; Yamazaki, H.; Nelson, D.R. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab. Rev., 2011, 43(3), 346-361.
25. Sakuma, T.; Hieda, M.; Igarashi, T.; Ohgiya, S.; Nagata, R.; Nemoto, N.; Kamataki, T. Molecular cloning and functional analysis of cynomolgus monkey CYP1A2. Biochem. Pharmacol., 1998, 56(1), 131-139. (Pubitemid 28477460)
26. Nakanishi, Y.; Matsushita, A.; Matsuno, K.; Iwasaki, K.; Utoh, M.; Nakamura, C.; Uno, Y. Regional distribution of cytochrome p450 mRNA expression in the liver and small intestine of cynomolgus monkeys. Drug Metab. Pharmacokinet., 2010, 25(3), 290-297.
27. Yoda, N.; Emoto, C.; Date, S.; Kondo, S.; Miyake, M.; Nakazato, S.; Umehara, K.; Kashiyama, E. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes. Xnobiotica, 2012, 42(8), 719-730.
28. Sonnier, M.; Cresteil, T. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J. Biochem., 1998, 251(3), 893-898. (Pubitemid 28108986)
29. Zhang, Q.Y.; Dunbar, D.; Ostrowska, A.; Zeisloft, S.; Yang, J.; Kaminsky, L.S. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos., 1999, 27(7), 804-809. (Pubitemid 29297778)
30. Paine, M.F.; Hart, H.L.; Ludington, S.S.; Haining, R.L.; Rettie, A.E.; Zeldin, D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos., 2006, 34(5), 880-886.
31. Whitlock, J.P., Jr. Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 103-125. (Pubitemid 29222553)
32. Nishimura, M.; Koeda, A.; Suganuma, Y.; Suzuki, E.; Shimizu, T.; Nakayama, M.; Satoh, T.; Narimatsu, S.; Naito, S. Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab. Pharmacokinet., 2007, 22(3), 178-186.
33. Uno, Y.; Hosaka, S.; Matsuno, K.; Nakamura, C.; Kito, G.; Kamataki, T.; Nagata, R. Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkeyspecific CYP gene responsible for species differences in drug metabolism? Arch. Biochem. Biophys., 2007, 466(1), 98-105. (Pubitemid 47405072)
34. Uehara, S.; Murayama, N.; Yamazaki, H.; Uno, Y. A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. Xenobiotica, 2010, 40(9), 621-629.
35. Koskela, S.; Hakkola, J.; Hukkanen, J.; Pelkonen, O.; Sorri, M.; Saranen, A.; Anttila, S.; Fernandez-Salguero, P.; Gonzalez, F.; Raunio, H. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem. Pharmacol., 1999, 57(12), 1407-1413. (Pubitemid 29225104)
36. Su, T.; Bao, Z.; Zhang, Q.Y.; Smith, T.J.; Hong, J.Y.; Ding, X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res., 2000, 60(18), 5074-5079.
37. Uehara, S.; Murayama, N.; Nakanishi, Y.; Zeldin, D.C.; Yamazaki, H.; Uno, Y. Immunochemical detection of cytochrome p450 enzymes in liver microsomes of 27 cynomolgus monkeys. J. Pharmacol. Exp. Ther., 2011, 339(2), 654-661.
38. Inoue, S.; Howgate, E.M.; Rowland-Yeo, K.; Shimada, T.; Yamazaki, H.; Tucker, G.T.; Rostami-Hodjegan, A. Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica, 2006, 36(6), 499-513. (Pubitemid 43890729)
39. Uno, Y.; Matsuno, K.; Nakamura, C.; Utoh, M.; Yamazaki, H. Identification and characterization of CYP2B6 cDNA in cynomolgus macaques (Macaca fascicularis). J. Vet. Med. Sci., 2009, 71(12), 1653-1656.
40. Komori, M.; Kikuchi, O.; Sakuma, T.; Funaki, J.; Kitada, M.; Kamataki, T. Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450. Biochim. Biophys. Acta., 1992, 1171(2), 141-146. (Pubitemid 23023701)
41. Uno, Y.; Fujino, H.; Kito, G.; Kamataki, T.; Nagata, R. CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. Mol. Pharmacol., 2006, 70(2), 477-486. (Pubitemid 44092308)
42. Uno, Y.; Matsuno, K.; Nakamura, C.; Utoh, M.; Yamazaki, H. Identification and characterization of CYP2C18 in the cynomolgus macaque (Macaca fascicularis). J. Vet. Med. Sci., 2010, 72(2), 225-228.
43. Mankowski, D.C.; Laddison, K.J.; Christopherson, P.A.; Ekins, S.; Tweedie, D.J.; Lawton, M.P. Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver. Arch. Biochem. Biophys., 1999, 372(1), 189-196.
44. Uno, Y.; Uehara, S.; Kohara, S.; Murayama, N.; Yamazaki, H. Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan. Drug Metab. Dispos., 2010, 38(9), 1486-1492.
45. Jacqz, E.; Billante, C.; Moysan, F.; Mathieu, H. The non-human primate: a possible model for human genetically determined polymorphisms in oxidative drug metabolism. Mol. Pharmacol., 1988, 34(2), 215-217.
46. Lane, H.Y.; Deng, H.C.; Huang, S.M.; Hu, W.H.; Chang, W.H.; Hu, O.Y. Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population. Clin. Pharmacol. Ther., 1996, 60(6), 696-698. (Pubitemid 27025918)
47. Chida, M.; Yokoi, T.; Kosaka, Y.; Chiba, K.; Nakamura, H.; Ishizaki, T.; Yokota, J.; Kinoshita, M.; Sato, K.; Inaba, M.; Aoki, Y.; Gonzalez, F.J.; Kamataki, T. Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics, 1999, 9(5), 601-605.
48. Nishida, Y.; Fukuda, T.; Yamamoto, I.; Azuma, J. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics, 2000, 10(6), 567-570.
49. Yamazaki, H.; Okayama, A.; Imai, N.; Guengerich, F.P.; Shimizu, M. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica, 2006, 36(12), 1201-1209. (Pubitemid 44963419)
50. Uno, Y.; Matsuno, K.; Nakamura, C.; Utoh, M.; Yamazaki, H. Cloning, expression, and characterization of CYP3A43 cDNA in cynomolgus macaque (Macaca fascicularis). Drug Metab. Lett., 2009, 3(4), 228-233.
51. Koch, I.; Weil, R.; Wolbold, R.; Brockmöller, J.; Hustert, E.; Burk, O.; Nuessler, A.; Neuhaus, P.; Eichelbaum, M.; Zanger, U.; Wojnowski, L. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos., 2002, 30(10), 1108-1114.
52. Wrighton, S.A.; Brian, W.R.; Sari, M.A.; Iwasaki, M.; Guengerich, F.P.; Raucy, J.L.; Molowa, D.T.; Vandenbranden, M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol., 1990, 38(2), 207-213. (Pubitemid 20255306)
53. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P.B.; Daly, A.; Wrighton, S.A.; Hall, S.D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M.S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 2001, 27(4), 383-391. (Pubitemid 32268418)
54. Niwa, T.; Murayama, N.; Emoto, C.; Yamazaki, H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr. Drug Metab., 2008, 9(1), 20-33. (Pubitemid 351201667)
55. Fukuen, S.; Fukuda, T.; Maune, H.; Ikenaga, Y.; Yamamoto, I.; Inaba, T.; Azuma, J. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics, 2002, 12(4), 331-334. (Pubitemid 34620661)
56. Saeki, M.; Saito, Y.; Nakamura, T.; Murayama, N.; Kim, S.R.; Ozawa, S.; Komamura, K.; Ueno, K.; Kamakura, S.; Nakajima, T.; Saito, H.; Kitamura, Y.; Kamatani, N.; Sawada, J. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum. Mutat., 2003, 21(6), 653.
57. Yamaori, S.; Yamazaki, H.; Iwano, S.; Kiyotani, K.; Matsumura, K.; Saito, T.; Parkinson, A.; Nakagawa, K.; Kamataki, T. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of coregulation of the expression of CYP3A in Japanese livers. Xenobiotica, 2005, 35(1), 69-83. (Pubitemid 40459218)
58. Uno, Y.; Matsushita, A.; Osada, N.; Uehara, S.; Kohara, S.; Nagata, R.; Fukuzaki, K.; Utoh, M.; Murayama, N.; Yamazaki, H. Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab. Dispos., 2010, 38(2), 209-214.
59. Uno, Y.; Uehara, S.; Murayama, N.; Yamazaki, H. CYP1D1, pseudogenized in human, is expressed and encodes a functional drugmetabolizing enzyme in cynomolgus monkey. Biochem. Pharmacol., 2011, 81(3), 442-450.
60. Shimada, T.; Gillam, E.M.; Sutter, T.R.; Strickland, P.T.; Guengerich, F.P.; Yamazaki, H. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab. Dispos., 1997, 25(5), 617-622. (Pubitemid 27213104)
61. Bogaards, J.J.; Bertrand, M.; Jackson, P.; Oudshoorn, M.J.; Weaver, R.J.; Van Bladeren, P.J.; Walther, B. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica, 2000, 30(12), 1131-1152. (Pubitemid 32368013)
62. Uno, Y.; Uehara, S.; Kohara, S.; Iwasaki, K.; Nagata, R.; Fukuzaki, K.; Utoh, M.; Murayama, N.; Yamazaki, H. Newly identified CYP2C93 is a functional enzyme in rhesus monkey, but not in cynomolgus monkey. PLoS One, 2011, 6(2), e16923.
63. Uno, Y.; Kumano, T.; Kito, G.; Nagata, R.; Kamataki, T.; Fujino, H. CYP2C76-mediated species difference in drug metabolism: a comparison of pitavastatin metabolism between monkeys and humans. Xenobiotica, 2007, 37(1), 30-43. (Pubitemid 46009555)
64. Uno, Y.; Matsuno, K.; Murayama, N.; Nakamura, C.; Yamazaki, H. Metabolism of P450 probe substrates by cynomolgus monkey CYP2C76. Basic Clin. Pharmacol. Toxicol., 2011, 109(4), 315-318.
65. Hanioka, N.; Yamamoto, M.; Iwabu, H.; Jinno, H.; Tanaka-Kagawa, T.; Naito, S.; Shimizu, T.; Masuda, K.; Katsu, T.; Narimatsu, S. Functional characterization of human and cynomolgus monkey cytochrome P450 2E1 enzymes. Life Sci., 2007, 81(19-20), 1436-1445. (Pubitemid 350018778)
66. Iwasaki, K.; Murayama, N.; Koizumi, R.; Uno, Y.; Yamazaki, H. Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. Drug Metab. Pharmacokinet., 2010, 25(4), 388-391.
67. Ohtsuka, T.; Yoshikawa, T.; Kozakai, K.; Tsuneto, Y.; Uno, Y.; Utoh, M.; Yamazaki, H.; Kume, T. Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. Drug Metab. Dispos., 2010, 38(10), 1806-1813.
68. Emoto, C.; Iwasaki, K.; Koizumi, R.; Utoh, M.; Murayama, N.; Uno, Y.; Yamazaki, H. Species difference between cynomolgus monkeys and humans on cytochromes P450 2D and 3A-dependent drug oxidation activities in liver microsomes. J. Health. Sci., 2011, 57(2), 164-170.
69. Patki, K.C.; Von Moltke, L.L.; Greenblatt, D.J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab. Dispos., 2003, 31(7), 938-944. (Pubitemid 36759065)
70. Houston, J.B.; Kenworthy, K.E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos., 2000, 28(3), 246-254. (Pubitemid 30137047)
71. Sakuda, S.; Akabane, T.; Teramura, T. Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. Xenobiotica, 2006, 36(4), 331-340.
72. Thummel, K.E.; O'Shea, D.; Paine, M.F.; Shen, D.D.; Kunze, K.L.; Perkins, J.D.; Wilkinson, G.R. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther., 1996, 59(5), 491-502. (Pubitemid 26193889)
73. Akabane, T.; Tabata, K.; Kadono, K.; Sakuda, S.; Terashita, S.; Teramura, T. A comparison of pharmacokinetics between humans and monkeys. Drug Metab. Dispos., 2010, 38(2), 308-316.
74. Wu, S.; Moomaw, C.R.; Tomer, K.B.; Falck, J.R.; Zeldin, D.C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem., 1996, 271(7), 3460-3468. (Pubitemid 26065653)
75. Matsumoto, S.; Hirama, T.; Matsubara, T.; Nagata, K.; Yamazoe, Y. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab. Dispos., 2002, 30(11), 1240-1245. (Pubitemid 35265831)
76. Hashizume, T.; Imaoka, S.; Mise, M.; Terauchi, Y.; Fujii, T.; Miyazaki, H.; Kamataki, T.; Funae, Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharmacol. Exp. Ther., 2002, 300(1), 298-304. (Pubitemid 34028540)
77. Kunze, K.L.; Trager, W.F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol., 1993, 6(5), 649-656. (Pubitemid 23290017)
78. Obach, R.S.; Walsky, R.L.; Venkatakrishnan, K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos., 2007, 35(2), 246-255. (Pubitemid 46148737)
79. Turpeinen, M.; Nieminen, R.; Juntunen, T.; Taavitsainen, P.; Raunio, H.; Pelkonen, O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab. Dispos., 2004, 32(6), 626-631. (Pubitemid 38668155)
80. Emoto, C.; Murase, S.; Sawada, Y.; Jones, B.C.; Iwasaki, K. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab. Pharmacokinet., 2003, 18(5), 287-295.
81. Ogasawara, A.; Kume, T.; Kazama, E. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab. Dispos., 2007, 35(3), 410-418. (Pubitemid 46333904)
82. Nishimuta, H.; Sato, K.; Mizuki, Y.; Yabuki, M.; Komuro, S. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Drug Metab. Dispos., 2010, 38(11), 1967-1975.
83. Gibbs, M.A.; Thummel, K.E.; Shen, D.D.; Kunze, K.L. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos., 1999, 27(2), 180-187. (Pubitemid 29072069)
84. Shimada, T.; Tsumura, F.; Yamazaki, H. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab. Dispos., 1999, 27(11), 1274-1280.
85. Watkins, P.B.; Wrighton, S.A.; Schuetz, E.G.; Molowa, D.T.; Guzelian, P.S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest., 1987, 80(4), 1029-1036. (Pubitemid 18075638)
86. Yamazaki, H.; Nakamura, M.; Komatsu, T.; Ohyama, K.; Hatanaka, N.; Asahi, S.; Shimada, N.; Guengerich, F.P.; Shimada, T.; Nakajima, M.; Yokoi, T. Roles of NADPH-P450 reductase and apo-and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr. Purif., 2002, 24(3), 329-337. (Pubitemid 35420057)
87. Hichiya, H.; Tanaka-Kagawa, T.; Soyama, A.; Jinno, H.; Koyano, S.; Katori, N.; Matsushima, E.; Uchiyama, S.; Tokunaga, H.; Kimura, H.; Minami, N.; Katoh, M.; Sugai, K.; Goto, Y.; Tamura, T.; Yamamoto, N.; Ohe, Y.; Kunitoh, H.; Nokihara, H.; Yoshida, T.; Minami, H.; Saijo, N.; Ando, M.; Ozawa, S.; Saito, Y.; Sawada, J. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab. Dispos., 2005, 33(5), 630-636. (Pubitemid 40593876)
88. Walsky, R.L.; Obach, R.S. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos., 2004, 32(6), 647-660. (Pubitemid 38668158)
89. Emoto, C.; Murase, S.; Iwasaki, K. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica, 2006, 36(8), 671-683. (Pubitemid 44195982)
90. Perloff, E.S.; Mason, A.K.; Dehal, S.S.; Blanchard, A.P.; Morgan, L.; Ho, T.; Dandeneau, A.; Crocker, R.M.; Chandler, C.M.; Boily, N.; Crespi, CL.; Stresser, D.M. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica, 2009, 39(2), 99-112.
91. Lin, T.; Pan, K.; Mordenti, J.; Pan, L. In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography. J. Pharm. Sci., 2007, 96(9), 2485-2493. (Pubitemid 47477901)
92. Emoto, C.; Murase, S.; Sawada, Y.; Iwasaki, K. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab. Pharmacokinet., 2005, 20(5), 351-357.
93. Emoto, C.; Iwasaki, K. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drugdiscovery stage: The effect of the expression of cytochrome b(5) with recombinant P450 enzymes. Xenobiotica, 2007, 37(9), 986-999. (Pubitemid 47482949)
94. Hickman, D.; Wang, J.P.; Wang, Y.; Unadkat, J.D. Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab. Dispos., 1998, 26(3), 207-215. (Pubitemid 28182395)
95. Wattanachai, N.; Polasek, T.M.; Heath, T.M.; Uchaipichat, V.; Tassaneeyakul, W.; Miners, J.O. In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur. J. Clin. Pharmacol., 2011, 67(8), 815-824.
96. Obach, R.S.; Zhang, Q.Y.; Dunbar, D.; Kaminsky, L.S. Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab. Dispos., 2001, 29(3), 347-352. (Pubitemid 32179537)
97. Kumar, S.; Samuel, K.; Subramanian, R.; Braun, M.P.; Stearns, R.A.; Chiu, S.H.; Evans, D.C.; Baillie, T.A. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J. Pharmacol. Exp. Ther., 2002, 303(3), 969-978. (Pubitemid 35424378)
98. Sharer, J.E.; Shipley, L.A.; Vandenbranden, M.R.; Binkley, S.N.; Wrighton, S.A. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos., 1995, 23(11), 1231-1241.
99. Galetin, A.; Houston, J.B. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of firstpass metabolism. J. Pharmacol. Exp. Ther., 2006, 318(3), 1220-1229. (Pubitemid 44268329)
100. Emoto, C.; Yamazaki, H.; Iketaki, H.; Yamasaki, S.; Satoh, T.; Shimizu, R.; Suzuki, S.; Shimada, N.; Nakajima, M.; Yokoi, T. Cooperativity of alpha-naphthoflavone in cytochrome P450 3Adependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica, 2001, 31(5), 265-275. (Pubitemid 32643307)
101. Cai, X.; Wang, R.W.; Edom, R.W.; Evans, D.C.; Shou, M.; Rodrigues, A.D.; Liu, W.; Dean, D.C.; Baillie, T.A. Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes. Drug Metab. Dispos., 2004, 32(6), 584-586. (Pubitemid 38668149)
102. Taavitsainen, P.; Juvonen, R.; Pelkonen, O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab. Dispos., 2001, 29(3), 217-222. (Pubitemid 32179519)
103. Walsky, R.L.; Obach, R.S. A comparison of 2-phenyl-2-(1-piperidinyl) propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab. Dispos., 2007, 35(11), 2053-2059. (Pubitemid 350005195)